Mutually-Assured Disruption

By Chuck Dinerstein, MD, MBA — Jan 30, 2024
Mutualism describes a relationship that benefits both parties – the win-win of our world. A new study reports on a mutualism that goes from ants to trees to elephants to lions and zebras. It serves as a reminder of the mutualism around us.

Mutualism describes a relationship that benefits both parties – the win-win of our world. A new study reports on a mutualism that goes from ants to trees to elephants to lions and zebras. It serves as a reminder of the mutualism around us.

America's Exploding Vaccination Crisis

By Henry I. Miller, MS, MD — Jan 30, 2024
Vaccination is a pillar of disease prevention, but Americans are under-vaccinated. We need a multi-pronged public education campaign with participation from politicians and celebrities of every stripe.

Vaccination is a pillar of disease prevention, but Americans are under-vaccinated. We need a multi-pronged public education campaign with participation from politicians and celebrities of every stripe.

A Consideration of Urban Waste

By Chuck Dinerstein, MD, MBA — Jan 29, 2024
Scaling often refers to the ability of a system, application, or network to handle an increasing amount of work, users, or data. Scalability in human behavior considers how individual actions aggregate to form group dynamics, social institutions, and even global phenomena. As we continue to urbanize and our cities grow larger, it is increasingly vital to understand not just the use of resources but the creation of waste.

Scaling often refers to the ability of a system, application, or network to handle an increasing amount of work, users, or data. Scalability in human behavior considers how individual actions aggregate to form group dynamics, social institutions, and even global phenomena. As we continue to urbanize and our cities grow larger, it is increasingly vital to understand not just the use of resources but the creation of waste.

The Witch-Trials Return: Rematch On Roundup

With the EPA finding that glyphosate is not likely to be carcinogenic to humans and the plaintiffs’ five-case winning streak against Bayer broken, things had been looking up on the Roundup event horizon. Alas, last week’s verdict dinged Roundup yet again. and some 40,000 cases are still pending. What can we expect next?

With the EPA finding that glyphosate is not likely to be carcinogenic to humans and the plaintiffs’ five-case winning streak against Bayer broken, things had been looking up on the Roundup event horizon. Alas, last week’s verdict dinged Roundup yet again. and some 40,000 cases are still pending. What can we expect next?

Proposing a Schedule Change for Marijuana

By Chuck Dinerstein, MD, MBA — Jan 26, 2024
“The Controlled Substances Act (CSA) places all substances that were in some manner regulated under existing federal law into one of five schedules. This placement is based on the substance’s medical use, potential for abuse, and safety or dependence liability.” The FDA has proposed changing the classification of marijuana from a Schedule I to a Schedule III drug. Let’s break down its thinking.

“The Controlled Substances Act (CSA) places all substances that were in some manner regulated under existing federal law into one of five schedules. This placement is based on the substance’s medical use, potential for abuse, and safety or dependence liability.” The FDA has proposed changing the classification of marijuana from a Schedule I to a Schedule III drug. Let’s break down its thinking.

Modern Salem-Witch-Trials 2: Rounding on Roundup

If Tylenol trials are off the table, what else tempts? How about the weed killer Roundup - the most popular and successful herbicide ever? Luckily for the plaintiff’s bar, there’s some evidence that it causes cancer. There’s also sound evidence that it doesn’t. Eighteen cases have gone to verdict. Bayer (which owns Monsanto, the product’s developer) won ten; the plaintiffs won eight. So, is the stuff human-harmful or not? Who decides in a court of law and how? And what’s next?

If Tylenol trials are off the table, what else tempts? How about the weed killer Roundup - the most popular and successful herbicide ever? Luckily for the plaintiff’s bar, there’s some evidence that it causes cancer. There’s also sound evidence that it doesn’t. Eighteen cases have gone to verdict. Bayer (which owns Monsanto, the product’s developer) won ten; the plaintiffs won eight. So, is the stuff human-harmful or not? Who decides in a court of law and how? And what’s next?

The Media and I: The Current State Of The COVID-19 Pandemic

By Henry I. Miller, MS, MD — Jan 25, 2024
In this radio conversation, John Batchelor and I discuss the effectiveness of vaccines and the challenges posed by new variants of SARS-CoV-2 (the virus that causes COVID-19) such as the now-dominant JN.1.

In this radio conversation, John Batchelor and I discuss the effectiveness of vaccines and the challenges posed by new variants of SARS-CoV-2 (the virus that causes COVID-19) such as the now-dominant JN.1.

These New Synthetic Opioids Could Make the Fentanyl Crisis Look like ‘The Good Old Days’

By Josh Bloom — Jan 23, 2024
Prohibition of drugs simply doesn't work. Clamping down on Percocet and Vicodin resulted in a surge in heroin use. Fentanyl took care of that market and now even worse drugs called nitazenes are being found in fentanyl samples. Dr. Jeff Singer and I discuss this latest development in USA Today

Prohibition of drugs simply doesn't work. Clamping down on Percocet and Vicodin resulted in a surge in heroin use. Fentanyl took care of that market and now even worse drugs called nitazenes are being found in fentanyl samples. Dr. Jeff Singer and I discuss this latest development in USA Today

Every Picture Tells A Story – Vaping and Quitting Smoking The Cochrane Report

By Chuck Dinerstein, MD, MBA — Jan 23, 2024
“There is high‐certainty evidence that ECs [electronic cigarettes] with nicotine increase quit rates compared to NRT [nicotine replacement therapy] and moderate‐certainty evidence that they increase quit rates compared to ECs without nicotine.” That is the initial statement by the Cochrane Group in its current report on electronic cigarettes. Care to know more?

“There is high‐certainty evidence that ECs [electronic cigarettes] with nicotine increase quit rates compared to NRT [nicotine replacement therapy] and moderate‐certainty evidence that they increase quit rates compared to ECs without nicotine.” That is the initial statement by the Cochrane Group in its current report on electronic cigarettes. Care to know more?